EssilorLuxottica’s Board of Directors met today and paid homage to Chairman, Leonardo Del Vecchio, who passed away peacefully yesterday morning. He will be remembered for his values, robust leadership, passion, exceptional character as well as his dedication toward the Company and its employees.  

During the meeting, the Board of Directors appointed Francesco Milleri as its new Chairman for the remaining duration of his mandate. Francesco Milleri will also carry on assuming his term of office as Chief Executive Officer of EssilorLuxottica.  

The Board further decided to examine the benefits of appointing a lead director among its independent members. A final decision will be taken in this regard before year-end. 

The Board further confirmed Paul du Saillant as Deputy Chief Executive Officer of EssilorLuxottica. 

During the same meeting, the Board also co-opted Mario Notari as a new Director. Mario Notari is full Professor of Company and Business Law at Università Bocconi in Milan and member, Phd Board in Business Law at Università Bocconi. He is also founder and partner of “ZNR notai”, public notaries and lawyers in Milan. He was Director of Luxottica Group S.p.A. from 2015 to 2018 and is a Director of Delfin S.à r.l.  

Mr. Notari will be considered as a non-independent director on the Board of EssilorLuxottica. His appointment will be submitted to shareholders’ vote at the next Annual General Shareholders’ Meeting of the Company.

Source: EssilorLuxottica

More than 1,000 eye care professionals (ECPs) and researchers from the Netherlands and around the world are expected to attend the 2022 Dutch Contact Lens Congress (NCC) from June 26-27 in Eindhoven. Among them will be scientists presenting a spectrum of new findings supported by CooperVision at the NCC and the British Contact Lens Association (BCLA) collaborative research symposium, further advancing understanding of high-value clinical and practice success topics.

“By investing in and disseminating research into some of the timeliest topics in contact lenses and eye care, CooperVision is extending our commitment to help improve clinical outcomes, increase patient satisfaction, and grow the category. The papers and posters being presented at NCC 2022 offer new evidence-based insights that elevate ocular science and provide practical guidance for ECPs,” said Francis Erard, Vice President of Research & Development for CooperVision.

CONTEMPORARY PRESBYOPIA MANAGEMENT

About one in three contact lens wearers today are presbyopic, which is an approximately 75% increase from two decades ago. And although multifocal contact lens fits are on the rise, they still represent about only half of lenses worn by presbyopes—representing significant growth opportunities. To support multifocal contact lens wear as presbyopia management interest becomes more prominent, CooperVision is sharing three works on the subject.

Led by a team from Ocular Technology Group, two papers focus on predicting the success of multifocal wear to build confidence among fitters. Prediction of Intention to Purchase of Multifocal Contact Lenses at Time of Dispensing (Guillon M, et al.) and Comparison of Overall Vision Satisfaction of a Multifocal Contact Lens on Dispensing and After 1-week Daily Wear to Predict Success (Guillon M, et al.) indicate that good vision at the time of dispensing is an indicator of future success.

A separate CooperVision poster is intended to extend similar confidence to ECPs prescribing recently launched MyDay® multifocal contact lenses. Wearer Experience and Eye Care Professional Acceptance with a New 1 Day Multifocal Contact Lens (McParland M, et al.) demonstrates that ‘real world’ success and wearer satisfaction for vision, comfort and overall performance were comparable to previously reported clinical trials, plus fast and easy fitting for ECPs.

BETTER OUTCOMES FOR ASTIGMATC PATIENTS

As a global leader in toric contact lenses, CooperVision is constantly adding to a body of knowledge that helps ECPs garner better outcomes for astigmatic patients. This includes being as particular as possible in addressing astigmatism in making lens choices.

A CORE-led paper— Performance Evaluation of Two Toric Multifocal Contact Lenses Available in Different Parameter Increments (Luensmann D, et al)—suggests that fitting a toric lens that offers more axis steps (5- vs. 10-degree increments) and more near adds (6 vs. 2 options) may contribute to better patient-reported vision outcomes. Aligning with that theme, a Eurolens-authored paper—Clinical Performance of Spherical vs. Toric Soft Contact Lenses in Low and Moderate Astigmats (Mirza A, et al.)—reflected clinically meaningful superiority in visual acuity with a toric lens and very similar comfort comparing the toric lens to the sphere. This suggests ECPs should prescribe low astigmats with toric lenses for full visual correction understanding that the comfort is the same.

MYOPIA MANAGEMENT, CATEGORY GROWTH & MORE

The company will deliver a paper on its groundbreaking seven-year MiSight® 1 day* contact lens clinical trial. Twelve months following treatment cessation, mean axial elongation data indicated no evidence of rebound effect, signifying the myopia control gains were retained among the entire cohort.  

A poster on young adult perceptions of contact lens wear, derived from new European data, offers insights into mechanisms that ECPs can employ to potentially increase new fits as well as promote dual wear of contact lenses and spectacles. A paper on using the OptiExpert™ online fitting app to support contact lens selection offers encouragement for technology-aided practice success.

Also traveling to Eindhoven are CooperVision FORCE (Future Ocular Research Creativity Event) student honorees from the University of Salento and Aston University, sharing research on the effectiveness of Biofinity Energys for accommodative support and the optimization of blink exercises using a dedicated digital app, respectively.

Click HERE for the full press release.